Cart
sales@molnova.com
RO7185876
CAS No. 2226038-71-5
RO7185876( —— )
Catalog No. M35141 CAS No. 2226038-71-5
RO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRO7185876
-
NoteResearch use only, not for human use.
-
Brief DescriptionRO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.
-
DescriptionRO7185876 is a potent and selective gamma secretase modulator as a potential research for Alzheimer's disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGamma-secretase
-
RecptorGamma-secretase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2226038-71-5
-
Formula Weight483.532
-
Molecular FormulaC25H28F3N7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C=1N=C2[C@@H](CCCCN2N1)C3=C(F)C(F)=C(F)C=C3)[C@H]4[C@@]5(CN(C[C@]4(CC5)[H])C=6C=C(C)N=CN6)[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ratni H, et al. Discovery of RO7185876, a Highly Potent γ-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer's Disease. ACS Med Chem Lett. 2020 Apr 27;11(6):1257-1268. ?
molnova catalog
related products
-
PEAQX
PEAQX(NVP-AAM 077) is an effective and orally available NMDA antagonist. It can inhibit human NMDA receptors for 1A/2A(IC50: 270 nM), rather than 1A/2B(29, 600 nM).
-
5β-Cholanic acid
5β-Cholanic acid (5beta-Cholanic acid) is a potent γ-secretase modulator used in Alzheimer's disease research.
-
Enoticumab
Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody with anticancer activity that inhibits the growth of cancer cells.Enoticumab binds human Dll4 and disrupts Notch-mediated signaling.
